Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 16:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Kailera will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.
May 27, 2026 10:40 ET | Source: Spherix Global Insights

Eli Lilly’s Oral GLP-1 Foundayo Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...
May 27, 2026 03:00 ET | Source: Zealand Pharma

Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions

Press release – No. 10 / 2026 Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as...
May 26, 2026 16:02 ET | Source: Kailera Therapeutics, Inc.

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
May 26, 2026 08:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
May 22, 2026 13:30 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

CHMP has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg in a single-dose pen for people living with obesity.
May 21, 2026 07:30 ET | Source: Antag Therapeutics

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer

Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment...
May 15, 2026 16:05 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer -...
May 13, 2026 07:30 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Hengrui Pharma and Kailera Therapeutics announce clinical data presentations at the American Diabetes Association 86th Scientific Sessions
May 12, 2026 16:05 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...